J 2011

Alleviation of extrapyramidal side effects upon switching from risperidone to paliperidone

PŘIKRYL, Radovan

Basic information

Original name

Alleviation of extrapyramidal side effects upon switching from risperidone to paliperidone

Authors

PŘIKRYL, Radovan (203 Czech Republic, guarantor, belonging to the institution)

Edition

Activitas Nervosa Superior Rediviva, Praha, Collegium Internationale Activitatis N.S, 2011, 1337-933X

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30000 3. Medical and Health Sciences

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

RIV identification code

RIV/00216224:14740/11:00060845

Organization unit

Central European Institute of Technology

Keywords in English

case report; clinical experience; extrapyr amidal side effects; paliperidone; treatment

Tags

Změněno: 16/4/2013 11:46, Olga Křížová

Abstract

V originále

Paliperidone is a new second generation antipsychotic; in terms of pharmacology, it is an active metabolite of risperidone. Compared to risperidone, paliperidone should thus show more stable occupation of dopamine receptors in the brain, which on one the hand may lead to increased antipsychotic efficacy, and on the other hand to reduced incidence of adverse extrapyramidal effects. The case report describes alleviation of Parkinson’s syndrome induced by risperidone by switching to paliperidone in a young man with a new occurrence of a paranoid schizophrenia episode. Thanks to its clinical efficacy, paliperi- done is ranked among the most successful second generation antipsychotics with reduced extrapyramidal symptomatology

Links

MSM0021622404, plan (intention)
Name: Vnitřní organizace a neurobiologické mechanismy funkčních systémů CNS
Investor: Ministry of Education, Youth and Sports of the CR, The internal organisation and neurobiological mechanisms of functional CNS systems under normal and pathological conditions.